Chiasma Reports on Significant Progress Made During 2017
08 janv. 2018 09h00 HE
|
Chiasma, Inc.
Initiated CHIASMA OPTIMAL Phase 3 Clinical Trial after SPA agreement with FDAAnnounces expected year-end 2017 cash and investments balance of approximately $67 millionContinues to expect existing cash...
Chiasma Reports Third Quarter 2017 Results
09 nov. 2017 16h05 HE
|
Chiasma, Inc.
WALTHAM, Mass., Nov. 09, 2017 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic...
Chiasma Recognizes Acromegaly Awareness Day
01 nov. 2017 08h50 HE
|
Chiasma, Inc.
WALTHAM, Mass., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Chiasma, Inc. (Nasdaq:CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic...
Chiasma Announces First Patient Is Randomized in Phase 3 CHIASMA OPTIMAL Clinical Trial of Octreotide Capsules in Patients with Acromegaly
27 sept. 2017 16h05 HE
|
Chiasma, Inc.
WALTHAM, Mass., Sept. 27, 2017 (GLOBE NEWSWIRE) -- Chiasma, Inc. (Nasdaq:CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic...
Chiasma Reports Second Quarter 2017 Results
10 août 2017 16h01 HE
|
Chiasma, Inc.
WALTHAM, Mass., Aug. 10, 2017 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic...
Chiasma Reaches Agreement with FDA Under Special Protocol Assessment for a New Phase 3 Clinical Trial of Octreotide Capsules in Acromegaly
10 août 2017 16h00 HE
|
Chiasma, Inc.
Chiasma plans to initiate enrollment in the new Phase 3 clinical trial – OPTIMAL – during second half of 2017Anticipates release of top-line data from new OPTIMAL trial by end of 2019Conference call...
Chiasma Appoints Roni Mamluk, Ph.D. to Board of Directors
19 juin 2017 08h18 HE
|
Chiasma, Inc.
WALTHAM, Mass., June 19, 2017 (GLOBE NEWSWIRE) -- Chiasma, Inc. (Nasdaq:CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic...
Chiasma Reports First Quarter 2017 Results
05 mai 2017 08h00 HE
|
Chiasma, Inc.
WALTHAM, Mass., May 05, 2017 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic...
Chiasma Announces Poster Presentation at ENDO 2017 on Evaluation of Acromegaly Symptoms from the Newly Developed Acromegaly Treatment Satisfaction Questionnaire
30 mars 2017 16h05 HE
|
Chiasma, Inc.
WALTHAM, Mass., March 30, 2017 (GLOBE NEWSWIRE) -- Chiasma, Inc. (Nasdaq:CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic...
Chiasma Reports Fourth Quarter and Year End 2016 Results
16 mars 2017 16h05 HE
|
Chiasma, Inc.
WALTHAM, Mass., March 16, 2017 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic...